Biodeterioration of low density polyethylene by mangrove associated endolichenic fungi and their enzymatic regimes

Fungal involvement in biodeterioration of Low Density Polyethylene (LDPE) has received a great attention in recent years. Among diverse groups of fungi, Endolichenic Fungi (ELF) are adapted to thrive in resource limited conditions. Present study was designed to investigate the potential of mangrove associated ELF, in biodeterioration of LDPE and to quantify key-depolymerizing enzymes. A total of 31 ELF species, isolated from 22 lichens of mangrove ecosystems in Negombo lagoon, Sri Lanka were identified using DNA barcoding techniques. ELF were inoculated into mineral salt medium, containing LDPE strips and incubated at 28±2°C, for 21 days, under laboratory conditions. After incubation, biodeterioration was monitored based on percent reductions in weights and tensile properties, increments in degree of water absorption, changes in peaks of Infrared spectra and surface erosions using Scanning Electron Microscopy. Out of 31 species, Chaetomium globosum, Daldinia eschscholtzii, Neofusicoccum occulatum, Phanerochaete chrysosporium, Schizophyllum commune and Xylaria feejeensis showed significant changes. Production of depolymerizing enzymes by these species, were assayed qualitatively using plate-based methods and quantitatively by mass level enzyme production. Among them Phanerochaete chrysosporium showed the highest enzyme activities as (9.69±0.04)x10^-3 , (1.96±0.01)x10^-3 , (5.73±0.03)x10^-3 , (0.88±0.01), (0.64±0.06), (1.43±0.01) U ml^-1 for laccase, lignin peroxidase, manganese peroxidase, amylase, lipase and esterase, respectively.

SAT0219 PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND RESOURCE UTILIZATION OF SJOGREN’S SYNDROME PATIENTS IN A LARGE US HEALTH NETWORK

Background:

Sjogren’s syndrome (SS) is a chronic progressive autoimmune disorder which occurs as primary (pSS) or secondary SS (sSS). With no approved disease modifying therapy, there is limited information on the treatment patterns and resource utilization among these patients (pts).

Objectives:

To describe pts characteristics, treatment patterns and healthcare resource utilization (HCRU) using electronic health records (EHR) of pts with pSS and sSS treated at the Providence St. Josephs Health system (PSJH).

Methods:

Pts ≥18 years of age with at least one clinical encounter with ICD-9-CM or ICD-10-CM diagnosis of SS, between Jan 2013 and Mar 2019 were included. Date of first encounter with SS diagnosis (index date) was used to assess pts demographics. Pt baseline comorbidities were evaluated during the 24 months pre-index period. Treatment patterns and HCRU were assessed during the 12 months post-index follow-up. Descriptive statistics were used to describe pts’ demographic and clinical characteristics, and medications use in the baseline and follow up.

Results:

Study cohort included 9,108 SS pts of which 76.5% had sSS diagnosis on index date. Majority of SS pts were women, Caucasian, with mean age of 58.3 yrs, and from western states in the US (Table 1). Endocrine conditions including hypo- and hyperthyroidism, and diabetes was the most common (45.5%) comorbidity at baseline, followed by rheumatologic disorders (25.6%) and neurological conditions (22.2%). Among patients with treatment information (4088, 44.88%), 42.95% were using symptomatic treatments for dry eye and mouth at baseline (Table 1). In the follow-up, SS pts had average 5.8 healthcare visits per patient per year (PPPY), including 0.6 inpatient and 3.4 outpatient visit respectively. About 40% of the SS pts (53.8% pSS and 35.8% sSS) were diagnosed by rheumatologists. Majority of the SS pts initiated treatment with cDMARDs (82%) and remained on the same treatment during 1 year follow-up (Fig 2).

Table 1.

Baseline Demographic and Clinical Pts Characteristics

SS Pts (n=9,108)DemographicsAge (years) on index date, mean (SD)58.3 (15.1)Female, n (%)8,338 (91.6)Caucasian, n (%)6.936 (76.2)Western Region, n (%)8,998 (98.8)Married, n (%)5,164 (56.7)Never Smoked, n (%)4,847 (53.2)Primary diagnosis, n (%)2,137 (23.5)Comorbidities, n (%)Cardiovascular1,408 (17.2)Endocrine3,733 (45.5)Oncology800 (9.8)Blood disorders1,221 (14.9)Pulmonary1,802 (22.0)Neurological1,821 (22.2)Liver/Kidney1,782 (21.7)Rheumatologic disorders2,096 (25.6)Autoimmune/ Immune related1,527 (18.6)Baseline Medications, n (%)Symptomatic11,756 (43.0)NSAIDs21,578 (38.6)cDMARDs31,435 (35.1)Corticosteroid41,393 (34.1)bDMARDs5266 (6.5)

1cevimeline, pilocarpine hydrochloride, ophthalmic insert etc;2aspirin, ibuprofen, naproxen;3methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, myophenolate mofetil, azathioprine;4prednisone;5sarilumab, belimumab, ustekinumab, infliximab, adalimumab, certolizumab pegol, golimumab, etanercept, abatacept, tocilizumab, rituximab, tofacitinib, baricitinib

Figure 1.

HCRU for pSS and sSS Pts

Figure 2.

Treatment Sequencing for pSS and sSS Pts. Note: Discontinued: pts who discontinued and didn’t advance to any therapy; same treatment: pts continued on index treatment till we have information.

Conclusion:

Observation of higher comorbidities suggests substantial burden of SS pts on healthcare system, with majority of pts being diagnosed outside of rheumatology offices.

Acknowledgments: :

We acknowledge the contributions of Manasi Suryavanshi towards drafting and reviewing the abstract.

Disclosure of Interests:

Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau, Joe Zhuo Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Roshanthi Weerasinghe Grant/research support from:., Qian Xia Shareholder of: I own shares of Bristol-Myers Squibb Company, Employee of: I am a paid employee of Bristol-Myers Squibb Company, Chidananda Samal Consultant of: I work as a consultant for Bristol-Myers Squibb Company, Niyati Sharma Consultant of: I work as a consultant for Bristol-Myers Squibb Company